{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:10:09Z","timestamp":1787962209978,"version":"build-2784847793"},"reference-count":90,"publisher":"Impact Journals, LLC","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,9,30]]},"DOI":"10.18632\/aging.203522","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T01:31:04Z","timestamp":1631842264000},"page":"21866-21902","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials"],"prefix":"10.18632","volume":"13","author":[{"given":"Qinglin","family":"Cheng","sequence":"first","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China"},{"name":"School of Medicine, Hangzhou Normal University, Hangzhou 310021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Chen","sequence":"additional","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjun","family":"Jia","sequence":"additional","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Fang","sequence":"additional","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"1","unstructured":"World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/."},{"key":"2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/heartjnl-2020-317901","article-title":"Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis.","volume":"10","author":"Park","year":"2021","journal-title":"Heart"},{"key":"3","doi-asserted-by":"publisher","first-page":"e0246182","DOI":"10.1371\/journal.pone.0246182","article-title":"Early risk markers for severe clinical course and fatal outcome in German patients with COVID-19.","volume":"1","author":"Marx","year":"2021","journal-title":"PLoS One"},{"key":"4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.arcmed.2020.09.010","article-title":"Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development.","volume":"5","author":"Ita","year":"2021","journal-title":"Arch Med Res"},{"key":"5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.14336\/AD.2020.1124","article-title":"A Comprehensive Summary of the Knowledge on COVID-19 Treatment.","volume":"1","author":"Su","year":"2021","journal-title":"Aging Dis"},{"key":"6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/14787210.2021.1863146","article-title":"An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies.","volume":"1","author":"Wong","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"7","doi-asserted-by":"publisher","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained.","volume":"10","author":"Caldwell","year":"2019","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"8","doi-asserted-by":"publisher","first-page":"n949","DOI":"10.1136\/bmj.n949","article-title":"Prophylaxis against covid-19: living systematic review and network meta-analysis.","volume":"37","author":"Darzi","year":"2021","journal-title":"BMJ"},{"key":"9","doi-asserted-by":"publisher","first-page":"e1003501","DOI":"10.1371\/journal.pmed.1003501","article-title":"Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.","volume":"1","author":"Hwang","year":"2020","journal-title":"PLoS Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1016\/j.jacc.2015.10.036","article-title":"Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials.","volume":"6","author":"Stone","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.","volume":"16","author":"Chang","year":"2018","journal-title":"Ann Intern Med"},{"key":"12","unstructured":"World Health Organization (WHO). Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/331501\/WHO-COVID-19-laboratory-2020.5-eng.pdf."},{"key":"13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jclinepi.2020.06.015","article-title":"The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application.","volume":"12","author":"Banzi","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"14","article-title":"Grading of recommendations assessment, development and evaluation.","author":"GRADE Working Group","year":"2017","journal-title":"The GRADE Working Group"},{"key":"15","doi-asserted-by":"crossref","unstructured":"World Health Organization. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected Interim Guidance. 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/331446\/WHO-2019-nCoV-clinical-2020.4-eng.pdf?sequence=1&isAllowed=y.","DOI":"10.15557\/PiMR.2020.0003"},{"key":"16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis.","volume":"15","author":"Salanti","year":"2013","journal-title":"Ann Intern Med"},{"key":"17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses.","volume":"6","author":"Guyatt","year":"2017","journal-title":"Syst Rev"},{"key":"18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.","volume":"38","author":"Bowdish","year":"2021","journal-title":"N Engl J Med"},{"key":"19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijid.2020.11.191","article-title":"A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.","volume":"10","author":"Kabir","year":"2021","journal-title":"Int J Infect Dis"},{"key":"20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","article-title":"Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.","volume":"9","author":"Boomars","year":"2021","journal-title":"Lancet Respir Med"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.31.21258081","article-title":"Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial.","author":"Schwartz","year":"2021","journal-title":"MedRxiv"},{"key":"22","doi-asserted-by":"publisher","first-page":"100981","DOI":"10.1016\/j.eclinm.2021.100981","article-title":"Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial.","volume":"3","author":"Galinskas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.22.21259318","article-title":"Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial.","author":"Nicolau","year":"2021","journal-title":"MedRxiv"},{"key":"24","doi-asserted-by":"publisher","first-page":"e13492","DOI":"10.7759\/cureus.13492","article-title":"Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial.","volume":"1","author":"Goren","year":"2021","journal-title":"Cureus"},{"key":"25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.","volume":"32","author":"Chen","year":"2021","journal-title":"JAMA"},{"key":"26","doi-asserted-by":"publisher","first-page":"100720","DOI":"10.1016\/j.eclinm.2020.100720","article-title":"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.","volume":"3","author":"Laso","year":"2021","journal-title":"EClinicalMedicine"},{"key":"27","first-page":"86","article-title":"Efficacies of lopinavir\/ritonavir and abidol in the treatment of novel coronavirus pneumonia.","volume":"3","author":"Lu","year":"2020","journal-title":"Chinese Journal of Infectious Diseases"},{"key":"28","doi-asserted-by":"publisher","first-page":"153494","DOI":"10.1016\/j.phymed.2021.153494","article-title":"Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients.","volume":"8","author":"Varshney","year":"2021","journal-title":"Phytomedicine"},{"key":"29","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.cmi.2021.03.005","article-title":"Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial.","volume":"2","author":"Guimard","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-296518\/v1","article-title":"Efficacy and safety of CT-P59 plus standard of care: a phase 2\/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection.","author":"Suh","year":"2021","journal-title":"Research Square"},{"key":"31","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","article-title":"Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.","volume":"9","author":"Coburn","year":"2021","journal-title":"Lancet Respir Med"},{"key":"32","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1055\/a-1414-5216","article-title":"Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial.","volume":"12","author":"Loustaunau","year":"2021","journal-title":"Thromb Haemost"},{"key":"33","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.","volume":"32","author":"Adams","year":"2021","journal-title":"JAMA"},{"key":"34","doi-asserted-by":"publisher","first-page":"100849","DOI":"10.1016\/j.eclinm.2021.100849","article-title":"Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.","volume":"3","author":"Erikstrup","year":"2021","journal-title":"EClinicalMedicine"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.27.21257096","article-title":"Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab.","author":"Sager","year":"2021","journal-title":"medRxiv"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.20.21256954","article-title":"Efficacy and safety of novel probiotic formulation in adult Covid19 outpatients: a randomized, placebo-controlled clinical trial.","author":"Espadaler-Mazo","year":"2021","journal-title":"medRxiv"},{"key":"37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cts.12840","article-title":"Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.","volume":"1","author":"German","year":"2020","journal-title":"Clin Transl Sci"},{"key":"38","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/s41467-021-22177-1","article-title":"Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.","volume":"1","author":"Winslow","year":"2021","journal-title":"Nat Commun"},{"key":"39","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1093\/cid\/ciaa1177","article-title":"Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial.","volume":"7","author":"Figueiredo","year":"2021","journal-title":"Clin Infect Dis"},{"key":"40","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.","volume":"32","author":"Reiersen","year":"2020","journal-title":"JAMA"},{"key":"41","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.","volume":"32","author":"Jaramillo","year":"2021","journal-title":"JAMA"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.30.21255934","article-title":"Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial.","author":"Chakladar","year":"2021","journal-title":"medRxiv"},{"key":"43","doi-asserted-by":"publisher","first-page":"668698","DOI":"10.3389\/fmed.2021.668698","article-title":"Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial.","volume":"8","author":"Onety","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-191648\/v1","article-title":"Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial.","author":"Bhatnagar","year":"2021","journal-title":"Research Square"},{"key":"45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"9","author":"Wilkinson","year":"2021","journal-title":"Lancet Respir Med"},{"key":"46","doi-asserted-by":"publisher","first-page":"100645","DOI":"10.1016\/j.eclinm.2020.100645","article-title":"Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.","volume":"2","author":"Daghfal","year":"2020","journal-title":"EClinicalMedicine"},{"key":"47","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1002\/jmv.26895","article-title":"A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients.","volume":"9","author":"Ischia","year":"2021","journal-title":"J Med Virol"},{"key":"48","doi-asserted-by":"publisher","first-page":"100957","DOI":"10.1016\/j.eclinm.2021.100957","article-title":"A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19.","volume":"3","author":"Bold","year":"2021","journal-title":"EClinicalMedicine"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2020-139065","article-title":"Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study).","author":"Malhotra","year":"2020","journal-title":"Postgrad Med J"},{"key":"50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.18433\/jpps32105","article-title":"Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.","volume":"2","author":"Sarfaraz","year":"2021","journal-title":"J Pharm Pharm Sci"},{"key":"51","doi-asserted-by":"publisher","first-page":"e216468","DOI":"10.1001\/jamanetworkopen.2021.6468","article-title":"Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.","volume":"4","author":"Milagres","year":"2021","journal-title":"JAMA Netw Open"},{"key":"52","doi-asserted-by":"publisher","first-page":"2003725","DOI":"10.1183\/13993003.03725-2020","article-title":"Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.","volume":"5","author":"Magri","year":"2021","journal-title":"Eur Respir J"},{"key":"53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.","volume":"38","author":"Ch\u00e1vez","year":"2021","journal-title":"N Engl J Med"},{"key":"54","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.03.21252509","article-title":"Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study.","author":"Enriquez","year":"2021","journal-title":"medRxiv"},{"key":"55","doi-asserted-by":"publisher","first-page":"2100752","DOI":"10.1183\/13993003.00752-2021","article-title":"Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial.","author":"Bergs\u00f8e","year":"2021","journal-title":"Eur Respir J"},{"key":"56","doi-asserted-by":"publisher","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.","volume":"17","author":"Cheng","year":"2020","journal-title":"Ann Intern Med"},{"key":"57","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.","volume":"38","author":"Lin","year":"2020","journal-title":"N Engl J Med"},{"key":"58","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.","volume":"9","author":"Pelletier","year":"2021","journal-title":"Lancet Respir Med"},{"key":"59","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.26.21250511","article-title":"The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19-a double-blind, randomized, placebo-controlled Phase 2 trial.","author":"Raud","year":"2021","journal-title":"medRxiv"},{"key":"60","doi-asserted-by":"publisher","first-page":"ofaa446","DOI":"10.1093\/ofid\/ofaa446","article-title":"Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients.","volume":"7","author":"Hrycko","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"61","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1186\/s13063-020-04813-1","article-title":"Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.","volume":"2","author":"Farizano Salazar","year":"2020","journal-title":"Trials"},{"key":"62","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.","volume":"39","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"63","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.","volume":"38","author":"Hosain","year":"2021","journal-title":"N Engl J Med"},{"key":"64","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.","volume":"14","author":"Mao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"65","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2665-9913(21)00070-9","article-title":"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.","volume":"3","author":"Wolski","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"66","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1093\/cid\/ciaa1443","article-title":"Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19).","volume":"7","author":"Marchini","year":"2021","journal-title":"Clin Infect Dis"},{"key":"67","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.","volume":"32","author":"Leclerc","year":"2020","journal-title":"JAMA"},{"key":"68","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12879-020-05507-4","article-title":"The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.","volume":"2","author":"Hajizadeh","year":"2020","journal-title":"BMC Infect Dis"},{"key":"69","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"9","author":"Hagino","year":"2021","journal-title":"Lancet Respir Med"},{"key":"70","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.","volume":"38","author":"Cruz","year":"2021","journal-title":"N Engl J Med"},{"key":"71","doi-asserted-by":"publisher","DOI":"10.1111\/aas.13941","article-title":"Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial.","author":"J\u00f8rgensen","year":"2021","journal-title":"Acta Anaesthesiol Scand"},{"key":"72","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.","volume":"38","author":"Del Sorbo","year":"2021","journal-title":"N Engl J Med"},{"key":"73","doi-asserted-by":"publisher","first-page":"000592021","DOI":"10.1183\/23120541.00059-2021","article-title":"A randomised trial ofin critically ill patients with COVID-19: ARMY-1.","volume":"7","author":"Agarwal","year":"2021","journal-title":"ERJ Open Res"},{"key":"74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","article-title":"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"75","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.","volume":"38","author":"Santoro","year":"2021","journal-title":"N Engl J Med"},{"key":"76","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.13.21256973","article-title":"A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19.","author":"Musser","year":"2021","journal-title":"medRxiv"},{"key":"77","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.01.21256470","article-title":"Lenzilumab efficacy and safety in newly hospitalized covid-19 subjects: results from the live-air phase 3 randomized double-blind placebo-controlled trial.","author":"Badley","year":"2021","journal-title":"medRxiv"},{"key":"78","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.15.20066266","article-title":"A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of \u03b1-Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19).","author":"Zhang","year":"2020","journal-title":"medRxiv"},{"key":"79","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis.","volume":"37","author":"Liu","year":"2020","journal-title":"BMJ"},{"key":"80","doi-asserted-by":"publisher","first-page":"bqab114","DOI":"10.1210\/endocr\/bqab114","article-title":"Do Anti-androgens Have Potential as Therapeutics for COVID-19?","volume":"16","author":"Mauvais-Jarvis","year":"2021","journal-title":"Endocrinology"},{"key":"81","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fimmu.2015.00361","article-title":"Modulating the Innate Immune Response to Influenza A Virus: Potential Therapeutic Use of Anti-Inflammatory Drugs.","volume":"6","author":"Fernandez-Sesma","year":"2015","journal-title":"Front Immunol"},{"key":"82","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1002\/jcp.26604","article-title":"Regulatory T and T helper 17 cells: Their roles in preeclampsia.","volume":"23","author":"Yousefi","year":"2018","journal-title":"J Cell Physiol"},{"key":"83","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaut.2010.12.005","article-title":"Virus expanded regulatory T cells control disease severity in the Theiler's virus mouse model of MS.","volume":"3","author":"Miller","year":"2011","journal-title":"J Autoimmun"},{"key":"84","doi-asserted-by":"publisher","first-page":"963689720925055","DOI":"10.1177\/0963689720925055","article-title":"Infection of Placental Extravillous Cytotrophoblasts with Human Cytomegalovirus Causes a Treg\/Th17 Imbalance at the Maternal-Fetal Interface.","volume":"2","author":"Zhang","year":"2020","journal-title":"Cell Transplant"},{"key":"85","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s43440-020-00195-y","article-title":"Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.","volume":"7","author":"Medhi","year":"2021","journal-title":"Pharmacol Rep"},{"key":"86","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.3390\/jcm10153236","article-title":"Benefits of Steroid Therapy in COVID-19 Patients with Different PaO\/FiORatio at Admission.","volume":"1","author":"Faraglia","year":"2021","journal-title":"J Clin Med"},{"key":"87","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s13054-020-03220-x","article-title":"Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial.","volume":"2","author":"Hebbar","year":"2020","journal-title":"Crit Care"},{"key":"88","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/jmv.25961","article-title":"Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.","volume":"9","author":"Ramachandran","year":"2020","journal-title":"J Med Virol"},{"key":"89","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cmi.2020.10.036","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.","volume":"2","author":"Kashour","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"90","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.","volume":"3","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T15:38:30Z","timestamp":1633448310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":90,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,9,30]]}},"alternative-id":["203522","34531332"],"URL":"https:\/\/doi.org\/10.18632\/aging.203522","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}